We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years.In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since the show’s debut. “This week we're celebrating the show's 20th anniversary, a little over a month late, but better late than never. Given that Mad Money’s been on the air for more than two decades now, I think it's worth going over the best-performing stocks during that period.” READ ALSO Jim Cramer Recently Discussed These 9 Stocks and Jim Cramer Commented on These 8 Stocks Recently He pointed out that while the broader markets have posted impressive long-term gains, the Dow rising 272%, the S&P 500 climbing 358%, and the Nasdaq 100 soaring 1,182%, the show’s philosophy has not changed. He said, "I created this show because I believe you can beat the averages by doing the homework and picking great individual stocks." Two decades later, he feels even more strongly about that belief. According to him, investing in high-quality companies with long-term potential can outperform those indices. “So, looking at every US-listed stock with a market cap of at least $1 billion and putting aside everything that came public after March 14th, 2005, the day of our first show, what are the biggest winners since Mad Money first went on the air? I've gotta tell you what, I love this list.” He also said the results were unexpected and would surprise viewers. Cramer framed these companies as real-world evidence of the show's long-held thesis, that investors who commit to studying individual businesses and hold onto strong performers over time can generate significant returns. Cramer noted that since Mad Money's launch in March 2005, “These winners really represent the core thesis of the show that you can make a killing by picking the right stocks, doing the homework and sticking with the great ones.” “Bottom line: When you look at the 10 best-performing stocks of the last 20-odd years, so many of these were gettable if you simply believed in your ability to pick stocks and stuck with them for the long haul.” Our Methodology For this article, we compiled a list of 20 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on April 28 and 29. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey’s database of over 1,000 hedge funds. Story Continues Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now? A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Number of Hedge Fund Holders: 68 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was discussed during the episode, and here’s what Mad Money’s host had to say: “Rearrange Repligen’s ticker just a bit and you'll get the ninth best stock of the Mad Money era, Regeneron Pharma, that's up more than 9,400%. Now this one's special to me because Regeneron’s co-founder and CEO, Dr. Len Schleifer, he was one of the first guests who ever came on the show back in April 12th, 2005. The stock was trading at less than five bucks a share. Now it's at $568, and that's after 6.87% beating today. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) develops and markets treatments for different health conditions. The company also focuses on creating new therapies for a range of medical problems. Overall RGEN ranks 9th on our list of the best performing stocks of the last 20 years according to Jim Cramer. While we acknowledge the potential of RGEN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RGEN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires Disclosure: None. This article is originally published at Insider Monkey. View Comments
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...